Piflufolastat F18 vs Rituximab
Piflufolastat F18 vs Rituximab: Overview
This comparison examines the pharmacological differences between Piflufolastat F18 and Rituximab.
Mechanism of Action
Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.
Pharmacokinetics
Half-life: Rituximab — 22 days.
Chemical Properties
Type: Piflufolastat F18 — Small molecule; Rituximab — Antibody.